Genkyotex provides Q4 business update and reports cash position. This press release may contain forward-looking statements by the company with respect to its objectives. 2021; 2020; 2019; 2018; 2017; 2016; 2015; 2014; 2020-12-08 - 07:00. Each publication will be released after Euronext market closing. Any forward-looking statements contained in this press release represent Calliditas’’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Find helpful customer reviews and review ratings for Nihon minshuÌ„ bunka no genkyoÌ„ : hisabetsu buraku no minzoku to geinoÌ„ at Amazon.com. This press release may contain forward-looking statements by the company with respect to its objectives. Genkyotex Announces 2020 Annual Financial Results and Provides Corporate Update * Cash runway until early March 2021 * Beyond early March 2021 a … Shareholders’ … The present review briefly highlights this hypothesis and discusses some interesting related pharmacological targets. Press releases / 2017 Press release . Next financial press release: Q3 2020 business update and cash position: October 22, 2020 (after market) About Genkyotex Genkyotex is the leading biopharmaceutical company in … 2021; 2020; 2019; 2018; 2017; 2016; 2015; 2014; Governance; OCABSA warrants; Shareholder information . *FREE* shipping on qualifying offers. For further information, please go to www.genkyotex.com. This press release is not a prospectus approved by the Financial Conduct Authority or any other UK regulatory authority for the purposes of Section 85 of the Financial Services and Markets Act 2000. On December 31, 2020, Genkyotex had cash and cash equivalents of €1.6 million. Its unique platform enables the identification of orally available small-molecules Next financial press release: Q1 2020 business update and cash position: April 23, 2020 (after market) About Genkyotex Genkyotex is the leading biopharmaceutical company in NOX therapies, listed on the Euronext Paris and Euronext Brussels markets. 2021; 2020; 2019; 2018; 2017; 2016; 2015; 2014; 2017-12-21 - 18:00. Highlights Fibrosis is a leading cause of organ failure Epithelial cells may represent the most promising cellular phenotype that could be exploited in the design of new anti-fibrotic medicines. Press release. On August 13, 2020, the Company announced the agreement by Calliditas to acquire 7,236,515 ordinary shares of Genkyotex, representing 62.7% of … Read honest … 2021; 2020; 2019; 2018; 2017; 2015; 2014; Other regulated information . Genkyotex Announces 2020 Annual Financial Results And Provides Corporate Update. 2017-08-03 - 17:45. About Genkyotex Genkyotex is the leading biopharmaceutical company in NOX … Genkyotex provides business update and reports cash position at September 30, 2019. Press releases Press releases. This data includes pre-determined secondary efficacy analyses that were not available earlier, in addition to full safety data. *FREE* shipping on qualifying offers. The Company expects that its current cash position is sufficient to fund planned operations to … Genkyotex provides business update for Q3 2017. Jidō gyakutai: Sono genkyō to keiji hōteki kainyū (Japanese Edition) Press release; Project presentation; Documentation; Shareholders general meeting 2021; 2020; 2019; 2018; 2017; 2016; 2015; 2014; Events and presentations; Regulated information. For further information, please go towww.genkyotex.com Disclaimer This press release may contain forward-looking statements by the company with respect to … Fibrosis, which affects millions of individuals worldwide, is a leading cause of organ failure. Genkyotex Announces 2020 Annual Financial Results And Provides Corporate Update Genkyotex provides Q4 business update and reports cash position Genkyotex announces update for near term clinical development plan for setanaxib Disclaimer This press release may contain forward-looking statements by the company with respect to its objectives. This press release does not constitute an offer to purchase, or a solicitation of an offer to sell, any securities of Genkyotex. 2017 first-half results. Genkyotex Extends Conversion Period for Outstanding €1.6 Million Convertible Debt by 12 Months. Genkyotex’s setanaxib granted Orphan Drug Designation by the European Commission for the treatment of PBC . Financial information. Genkyotex Announces 2020 Annual Financial Results And Provides Corporate Update, Genkyotex provides Q4 business update and reports cash position, Genkyotex announces update for near term clinical development plan for setanaxib, Genkyotex announces positive Phase 1 results demonstrating a favorable safety and pharmacokinetic profile of high-dose setanaxib, Genkyotex’s setanaxib granted Orphan Drug Designation by the European Commission for the treatment of PBC, Genkyotex announces the closing of the acquisition by Calliditas Therapeutics of a controlling interest in Genkyotex, Genkyotex provides business update and reports cash position at September 30, 2020, Genkyotex’s setanaxib granted Orphan Drug Designation by the US FDA for the treatment of PBC, Genkyotex announces first-half 2020 results and business update, Genkyotex announces the enrollment of the 1st patient in the Phase 2 trial of setanaxib in idiopathic pulmonary fibrosis (IPF), Genkyotex announces agreement for Calliditas Therapeutics to acquire controlling interest in Genkyotex SA, Genkyotex provides business update and reports cash position at June 30, 2020, Genkyotex announces the dosing of the first subjects in its Phase 1 study with high-dose setanaxib, Genkyotex provides new clinical data from the PBC Phase 2 trial providing further evidence of the anti-fibrotic activity of setanaxib, Genkyotex receives approval from the ANSM to initiate a Phase 1 clinical study with high-dose setanaxib, Genkyotex provides business update and reports cash position at March 31, 2020, Genkyotex’s setanaxib significantly improves immunotherapy including checkpoint inhibitors in multiple preclinical cancer models, Genkyotex announces 2019 annual financial results and provides corporate update, Genkyotex raises €4.9 million in its rights issue, Genkyotex announces its financial calendar for 2020, Genkyotex launches a rights issue for a maximum amount of €6.13 million, Genkyotex provides business update and reports gross cash position at December 31, 2019, Half-yearly report on Genkyotex’s liquidity contract with Kepler Cheuvreux, Genkyotex reports progress of Setanaxib phase 2 investigator initiated trials, Genkyotex provides business update and reports cash position at September 30, 2019, Genkyotex Announces First Half 2019 Results, Genkyotex Extends Conversion Period for Outstanding €1.6 Million Convertible Debt by 12 Months, Genkyotex announces positive post-hoc analysis of PBC phase 2 trial and reports cash position at june 30, 2019, The WHO recognizes NOX inhibitors as new therapeutic class and approves SETANAXIB for GKT831, Genkyotex Announces FDA Approval of Phase 2 Investigator-Initiated Trial with GKT831 in IPF, Genkyotex’s GKT831 prevents multiple complications of portal hypertension in preclinical model, Result of the vote on the resolutions - Combined General Meeting of June 13, 2019 at 10 am (French), Registration Document including the Annual Financial Report 2018, Notice of Meeting - Shareholders' General Meeting of June 13, 2019 (French), Genkyotex invites shareholders to annual general meeting on June 13, 2019, Publication of GKT831 data in the Journal of Hepatology, Genkyotex Reports Clinical Evidence of Anti-fibrotic Activity by GKT831 in Liver Fibrosis Patients, Genkyotex Conference Call at 2pm Paris time on 2nd MayGenkyotex Conference Call at 2pm Paris time on 2nd May, Genkyotex provides corporate update and reports cash position at March 31, 2019, Genkyotex to present updated interim results from Phase 2 trial of GKT831 in primary biliary cholongitis at 2019 EASL International Liver Congress (ILC), Genkyotex reverse stock split takes effect, Genkyotex Announces Completion of 24-Week Treatment Period of its Phase 2 Trial with GKT831 in PBC, Genkyotex announces 2018 annual financial results and provides corporate update, Launch of the reverse stock split of Genkyotex shares, Genkyotex to Present Corporate Overview at Two Upcoming NASH Conferences, Genkyotex Announces Award of Grant from Cancer Research UK to Academic Partner to Further Develop NOX Research in Oncology, Genkyotex Provides Corporate Update and Reports Cash Position at December 31, 2018, Genkyotex announces the approval of reverse stock split by its shareholders and provides business update, Genkyotex announces its financial calendar for 2019, Genkyotex announces the enrollment of the 1. Genkyotex’s setanaxib granted Orphan Drug Designation by the European Commission for the treatment of PBC, Genkyotex announces the closing of the acquisition by Calliditas Therapeutics of a controlling interest in Genkyotex, Genkyotex provides business update and reports cash position at September 30, 2020, Genkyotex’s setanaxib granted Orphan Drug Designation by the US FDA for the treatment of PBC, Genkyotex announces first-half 2020 results and business update, Genkyotex announces the enrollment of the 1st patient in the Phase 2 trial of setanaxib in idiopathic pulmonary fibrosis (IPF), Genkyotex announces agreement for Calliditas Therapeutics to acquire controlling interest in Genkyotex SA, Genkyotex provides business update and reports cash position at June 30, 2020, Genkyotex announces the dosing of the first subjects in its Phase 1 study with high-dose setanaxib, Genkyotex provides new clinical data from the PBC Phase 2 trial providing further evidence of the anti-fibrotic activity of setanaxib, Genkyotex receives approval from the ANSM to initiate a Phase 1 clinical study with high-dose setanaxib, Genkyotex provides business update and reports cash position at March 31, 2020, Genkyotex’s setanaxib significantly improves immunotherapy including checkpoint inhibitors in multiple preclinical cancer models, Genkyotex announces 2019 annual financial results and provides corporate update, Genkyotex raises €4.9 million in its rights issue, Genkyotex announces its financial calendar for 2020, Genkyotex launches a rights issue for a maximum amount of €6.13 million, Genkyotex provides business update and reports gross cash position at December 31, 2019, Half-yearly report on Genkyotex’s liquidity contract with Kepler Cheuvreux, Genkyotex announces the enrollment of the 1. 2021; 2020; 2019; 2018; 2017; 2016; 2015; 2014; 2021-02-18 - 19:15. Press releases / 2020 Press release . 2021-01-27 - 10:00 . For further information, please go to www.genkyotex.com. 2021-01-22 - 07:00. This press release may contain forward-looking statements by the company with respect to its objectives. 2020-11-03 - 15:15. Based on the total number of issued shares and voting rights of Genkyotex on the date of this press release (11,548,562) In the exhibition »no no noh« the Japanese artist Leiko Ikemura, who resides in Europe for many years now, her own works with a selection of drawings by Walter Pichler, taken from the collection of Diethard Leopold. Genkyotex announces update for near term clinical development plan for setanaxib. Genkyotex announces the closing of the acquisition by Calliditas Therapeutics of a controlling interest in Genkyotex. Genkyotex announces its financial calendar for 2018. This press release may contain forward-looking statements by the company with respect to its objectives. 2017-10-26 - 18:00 . This press release may contain forward-looking statements by the company with respect to its objectives. Press Release; Installationshots; Artists; Selected works; #BEvienna; Leiko Ikemura presented in dialog with selected works from the Diethard Leopold Collection. Jidō gyakutai: Sono genkyō to keiji hōteki kainyū (Japanese Edition) [Hayashi, Hiromasa] on Amazon.com. Disclaimer This press release may contain forward-looking statements by the company with respect to … This press release may contain forward-looking statements by the company with respect to its objectives. 2020-10-22 - 18:30. 2017-09-21 - 18:45. Genkyotex announces positive post-hoc analysis of PBC phase 2 … Press release; Project presentation; Documentation; Shareholders general meeting; Press releases. For 40 years myofibroblasts have been recognized to be the key cellular players in fibrosis. Get the latest GENKYOTEX (GKTX.PA) stock news and headlines to help you in your trading and investment decisions. Nihon no genkyō Kumano (Japanese Edition) [Takeshi Umehara] on Amazon.com. Genkyotex has reported positive final results of its Phase II trial of anti-fibrotic candidate GKT831 in primary biliary cholangitis (PBC).